腎臟藥物市場：依給藥途徑、按藥物類別、按分銷管道、按地區

預計2024年全球腎臟藥物市場規模為172億美元，預計2031年將達269億美元，2024年至2031年複合年成長率為6.6%。

圖 1. 2024 年腎臟藥物市場佔有率（%），依地區分類

由於全球腎臟疾病盛行率不斷上升，全球腎臟藥物市場正在強勁成長。腎臟或腎臟疾病已成為一個主要的公共衛生問題，對老年人口的影響尤其嚴重。根據美國腎臟資料系統的數據，超過 661,000 名美國患有末期腎臟病，而且這一數字預計在不久的將來還會增加。此外，糖尿病和高血壓等疾病是腎臟疾病的主要原因，也推動了對用於治療和管理的腎臟藥物的需求。製藥公司正在積極致力於開發新的有效藥物，以滿足不斷成長的需求。

市場動態：

全球腎病藥物市場的成長是由更容易患慢性腎臟病的老年人口增加、糖尿病和高血壓患病率上升、人們對腎病的認知提高以及旨在開發新治療方法的研究工作取得進展推動的。然而，藥物核准的嚴格法規環境以及與腎臟藥物相關的高成本可能會阻礙市場成長。新興國家不斷成長的醫療保健支出可能為市場進入者提供機會。製藥公司正在大力投資管道藥物的臨床試驗，以擴大產品系列，並進行併購以提高其市場佔有率。

本研究的主要特點

• 該報告對全球腎臟藥物市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
• 它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球腎臟藥物市場的主要企業。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
• 全球腎臟藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 相關人員可以透過用於全球腎臟藥物市場分析的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行概述
• 一致的機會地圖 (COM)

第3章 市場動態、法規與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管場景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球腎臟藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球腎臟病藥物市場，依途徑，2019-2031（十億美元）

• 介紹
• 口服
• 胃腸外的
• 其他

第6章全球腎臟病藥物市場，依藥物類別，2019-2031（十億美元）

• 介紹
• ACE抑制劑
• 血管收縮素受體阻斷劑 (ARB)
• B阻斷劑
• 鈣離子通道阻斷劑
• 袢利尿劑
• 紅血球生成刺激因子（ESA）
• 磷酸鹽粘合劑
• 其他

第7章全球腎臟藥物市場，按分銷管道，2019-2031（十億美元）

• 介紹
• 醫院藥房
• 零售藥房
• 網路藥房

第8章2019-2031年全球腎臟藥物市場（按地區）（十億美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第9章 競爭格局

• 公司簡介
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson &Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck &Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG &Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

第10章分析師建議

• 升起和降落
• 綜合機會圖

第11章 參考文獻與調查方法

• 參考
• 調查方法

Global nephrology drugs market is estimated to be valued at USD 17.2 Bn in 2024 and is expected to reach USD 26.9 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Figure 1. Nephrology Drugs Market Share (%), By Region, 2024

Global nephrology drugs market has been witnessing robust growth due to rising prevalence of kidney diseases around the world. Kidney or renal diseases have emerged as a major public health issue, disproportionately affecting the elderly population. According to the U.S. Renal Data System, over 661,000 Americans have end-stage renal disease with the number expected to grow in the near future. Moreover, conditions like diabetes and hypertension, which are the leading causes of kidney diseases, boosts demand for nephrology medications for treatment and management. Pharmaceutical companies are actively engaged in developing novel and effective drugs to cater to growing demand.

Market Dynamics:

Global nephrology drugs market growth is primarily driven by increasing geriatric population susceptible to chronic kidney diseases, rising prevalence of diabetes and hypertension, growing awareness about kidney ailments, and ongoing research towards development of new treatment options. However, stringent regulatory environment for drug approval and high costs associated with renal medication can hamper the market growth. Growing healthcare expenditure of emerging economies can offer opportunities for market players. Pharmaceutical companies are investing heavily in clinical trials of pipeline drugs to expand their product portfolios, and are engaging in mergers and acquisitions to strengthen their market presence.

Key features of the study:

• This report provides in-depth analysis of the global nephrology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nephrology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen, Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd., Sanofi S.A, AbbVie Inc., Novartis AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nephrology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephrology drugs market

Detailed Segmentation-

• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Drug Class
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Amgen Inc.
  • F.Hoffmann-La Roche Ltd
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Nephrology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Nephrology Drugs Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn) Myoglobin
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Nephrology Drugs Market, By Drug Class, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• ACE Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Angiotensin Receptor Blockers (ARBs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• B-Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Loop Diuretics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Phosphate Binders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Nephrology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Nephrology Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Reference and Research Methodology

• References
• Research Methodology
• About us and Sales Contact